Ingelheim, May 31, 2011 - Boehringer Ingelheim announced today the US-registration for the manufacturing of Bayer HealthCare’s Betaferon ® against multiple sclerosis. Recently Bayer HealthCare extended the commercial production agreement for Betaferon ® with Boehringer Ingelheim who received the FDA approval for Betaferon ® (US brand name: Betaseron ®) on May 2nd 2011. Focus of the strategic partnership between the two companies is to establish Boehringer Ingelheim as the global supplier for Betaferon®. The manufacturing approval for the US market is a very important milestone within this partnership.
The agreement covers manufacturing (in Vienna, Austria) and fill & finish (in Biberach, Germany) at Boehringer Ingelheim’s large-scale facilities.
Already in 1995 Boehringer Ingelheim started as contract manufacturer of Betaferon ® for the European market. “We are pleased to extend our longstanding and successful relationship with Bayer HealthCare,” stated Simon Sturge, Corporate Senior Vice President Biopharmaceuticals. “Boehringer Ingelheim is well prepared to meet the global market demands for Betaferon ®.”
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and with more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.
